1,255 reports of this reaction
2.8% of all PALIPERIDONE reports
#7 most reported adverse reaction
HYPERPROLACTINAEMIA is the #7 most commonly reported adverse reaction for PALIPERIDONE, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,255 FDA adverse event reports linking PALIPERIDONE to HYPERPROLACTINAEMIA. This represents approximately 2.8% of all 45,344 adverse event reports for this drug.
Patients taking PALIPERIDONE who experience hyperprolactinaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERPROLACTINAEMIA is a less commonly reported adverse event for PALIPERIDONE, but still significant enough to appear in the safety profile.
In addition to hyperprolactinaemia, the following adverse reactions have been reported for PALIPERIDONE:
The following drugs have also been linked to hyperprolactinaemia in FDA adverse event reports:
HYPERPROLACTINAEMIA has been reported as an adverse event in 1,255 FDA reports for PALIPERIDONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERPROLACTINAEMIA accounts for approximately 2.8% of all adverse event reports for PALIPERIDONE, making it a notable side effect.
If you experience hyperprolactinaemia while taking PALIPERIDONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.